Mereo BioPharma Group plc Directorate Change (6900L)
October 05 2016 - 2:00AM
UK Regulatory
TIDMMPH
RNS Number : 6900L
Mereo BioPharma Group plc
05 October 2016
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Directorate Change
London, 5 October 2016 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
and specialty diseases, today announces that Richard Bungay, the
Company's Chief Financial Officer and Chief Operating Officer, will
be leaving Mereo in order to pursue other business interests.
Richard will be leaving in April 2017 in order to ensure an orderly
transition. The search for a Chief Financial Officer is underway.
The Company has also initiated a search for a Head of
Pharmaceutical Development. Further announcements will be made in
due course.
Dr Peter Fellner, Chairman of Mereo BioPharma commented:
"On behalf of the Board I would like to thank Richard for his
significant contributions to the successful launch of the Company
and the subsequent introduction of its shares on AIM. We wish him
every success for the future."
For Further Enquiries:
Mereo BioPharma Group
plc +44 (0)333 023 7319
Denise Scots-Knight, Chief
Executive Officer
Nominated Adviser and
Joint Broker
Cantor Fitzgerald Europe +44 (0)20 7894 7000
Phil Davies
Joint Broker
RBC Capital Markets +44 (0)20 7653 4000
Rupert Walford
Public Relations Adviser
to Mereo Biopharma
FTI Consulting +44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
About Mereo
Mereo is a UK-based biopharmaceutical company focused on the
development of innovative medicines that aim to address unmet
medical needs in rare and specialty disease areas and improve
patient quality of life. The Company seeks to selectively acquire
development-stage product candidates with demonstrated clinically
meaningful data from large pharmaceutical companies and to rapidly
progress these product candidates to subsequent value inflection
points.
Mereo combines the operational discipline and efficiency of a
small company with the financial resources to conduct comprehensive
clinical studies. The Company has the option to directly
commercialise products, for example in orphan diseases, in addition
to partnering or divesting its products.
Mereo's initial portfolio consists of three mid-late stage
clinical assets that were acquired from Novartis in July 2015.
BPS-804 is being developed for the prevention of fractures
resulting from osteogenesis imperfecta (brittle bone disease);
BCT-197, is being developed to treat inflammation in patients with
an acute exacerbation of chronic obstructive pulmonary disease; and
BGS-649 is a once-weekly pill to restore normal testosterone levels
in men with hypogonadal hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with BCT-197
and a Phase 2b study with BGS-649. Mereo submitted its proposed
Phase 2b/3 pivotal study design package for BPS-804 to the
regulator in H1 2016 and expects to commence the trial during H1
2017, pending feedback from the regulator. Additional product
opportunities, from a range of large pharmaceutical companies, are
under active evaluation.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKMMGGKDFGVZM
(END) Dow Jones Newswires
October 05, 2016 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024